This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Atea Pharmaceuticals, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Ashleigh Shannon: Innovator in SARS-CoV-2 Therapy
Introduction
Ashleigh Shannon is a prominent inventor based in Marseille, France. She has made significant contributions to the field of pharmaceutical research, particularly in the development of therapies for viral infections.
Latest Patents
Ashleigh holds a patent for "NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY." This innovative work addresses the urgent need for effective treatments against SARS-CoV-2 variants, showcasing her commitment to advancing public health.
Career Highlights
Currently, Ashleigh is employed at Atea Pharmaceuticals, Inc., where she continues to push the boundaries of medical research. Her work is instrumental in the fight against viral diseases, and she is recognized for her expertise in drug development.
Collaborations
Throughout her career, Ashleigh has collaborated with notable professionals in the field, including Jean-Pierre Sommadossi and Kai Lin. These partnerships have enhanced her research and contributed to the success of her projects.
Conclusion
Ashleigh Shannon is a trailblazer in the pharmaceutical industry, with a focus on innovative therapies for viral infections. Her contributions are vital in the ongoing battle against diseases like COVID-19.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile